IAI CONFERENCE: Adverse drug reactions associated with successful treatment of multidrug-resistant tuberculosis patients in Cempaka Putih Islamic Hospital Central Jakarta
DOI:
https://doi.org/10.46542/pe.2021.212.1521Keywords:
Adverse drug reaction, Multi-drug resistance, Successful treatment, TuberculosisAbstract
Introduction: Indonesia experiences Tuberculosis (TB) cases that are very complex and complicated, especially those dealing with Multi-Drug Resistance TB (MDR-TB). Its therapy using several types of drugs can cause several problems; one of them is an adverse drug reaction.
Aim: To investigate the association between Adverse Drug Reactions (ADR) and the successful treatments of MDR-TB patients.
Method: This was a retrospective study, the population in this study were all patients with medical and treatment records for MDR-TB. This sampling type is a purposive sampling technique. The statistical analysis used the chi-square test as the statistical test.
Results: The significant correlation was between the incidence of ADRs and successful treatment with p=0.024; odd ratio=2.526; CI=1.193 - 17.892.
Conclusions: This study may help in formulating strategies for the timely and aggressive management of adverse drug reactions. This can reduce the deferral of therapy and increase the clinical success rate.
References
Asril I, Soetikno V, A.P. (2019). Associations between the adverse drug reactions and the tuberculosis treatment dropout rates at the Cempaka Putih Islamic Hospital in Jakarta, Indonesia. Journal of Natural Science, Biology and Medicine, 10(3), 29–33
D. Pranger, A., W.C. Alffenaar, J., & E. Aarnoutse, R. (2012). Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach. Current Pharmaceutical Design. https://doi.org/10.2174/138161211797470200
Dela, A., Tank, N.K., Singh, A., & Piparva, K. (2017). Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. Lung India, 34(6), 522. https://doi.org/10.4103/0970-2113.217569
El-Din, M.A.T., Halim, H.A. A.-E., & El-Tantawy, A.M. (2015). Adverse reactions among patients being treated for multi-drug resistant tuberculosis in Egypt from July 2006 to January 2009. Egyptian Journal of Chest Diseases and Tuberculosis, 64(3), 657–664. https://doi.org/10.1016/j.ejcdt.2015.05.011
Emil Ibrahim. (2018). Menyambut World TB Day 2018 : Peran RS dalam Penanggulangan TB-MDR di Indonesia. Ditjen Yankes Kemenkes RI
Gualano, G., Mencarini, P., Musso, M., Mosti, S., Santangelo, L., Murachelli, S., Cannas, A., Di Caro, A., Navarra, A., Goletti, D., Girardi, E., & Palmieri, F. (2019). Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. PLOS ONE, 14(2), e0212948. https://doi.org/10.1371/journal.pone.0212948
Hair, J. F., Black, W.C., Babin, B.J., & Anderson, R.E. (2010). Multivariate Data Analysis. In Vectors. https://doi.org/10.1016/j.ijpharm.2011.02.019
Jacobs, T., & Ross, A. (2012). Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinic. South African Family Practice, 54(6), 531–539. https://doi.org/10.1080/20786204.2012.10874288
Kamso, P.S., Manaf, A., Alamiahnya, R., Tuberkulosis, U. P., Tuberkulosis, P., Mutu, P., & Tb, L. (2011). Pedoman Nasional Penanggulangan Tuberkulosis edisi 2. Pedoman Nasional Penanggulangan Tuberkulosis Edisi 2
Kapadia V, Tripathi S, ST (2013). Analysis of 63 patients of MDR TB on DOTS plus regimen : An LG hospital , TB Unit , Ahmedabad experience . Gujarat Medical Journal, 68(2), 55–57
Kemenkes RI. (2014). Pedoman-Tbnasional2014. In Pedoman Nasional Pengendalian Tuberkulosis
Lange, C., Dheda, K., Chesov, D., Mandalakas, A.M., Udwadia, Z., & Horsburgh, C.R. (2019). Management of drug-resistant tuberculosis. The Lancet, 394(10202), 953–966. https://doi.org/10.1016/S0140-6736(19)31882-3
Merid, M.W., Gezie, L.D., Kassa, G.M., Muluneh, A.G., Akalu, T.Y., & Yenit, M.K. (2019). Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study. BMC Infectious Diseases, 19(1), 286. https://doi.org/10.1186/s12879-019-3919-1
Mulu, W., Mekkonnen, D., Yimer, M., Admassu, A., & Abera, B. (2015). Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. African Health Sciences, 15(2), 368. https://doi.org/10.4314/ahs.v15i2.9
Pranger, A.D., van der Werf, T.S., Kosterink, J.G. W., & Alffenaar, J.W.C. (2019). The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. Drugs, 79(2), 161–171. https://doi.org/10.1007/s40265-018-1043-y
Reviono, Kusnanto, Vicky Eko, Helena Pakiding, & Nurwidiasih, D. (2014). Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. Majalah Kedokteran Bandung, 46(4), 189–196
Schmit, K.M., Wansaula, Z., Pratt, R., Price, S.F., & Langer, A.J. (2017). Tuberculosis — United States, 2016. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6611a2
Shin, S.S., Pasechnikov, A.D., Gelmanova, I.Y., Peremitin, G.G., Strelis, A.K., Mishustin, S., Barnashov, A., Karpeichik, Y., Andreev, Y.G., Golubchikova, V.T., Tonkel, T.P., Yanova, G.V., Yedilbayev, A., Rich, M.L., Mukherjee, J.S., Furin, J.J., Atwood, S., Farmer, P.E., & Keshavjee, S. (2007). Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union against Tuberculosis and Lung Disease, 11(12), 1314–1320. http://www.ncbi.nlm.nih.gov/pubmed/18034952
Tae Won Yang, Md., , Hyun Oh Park, Md., , Ha Nee Jang, Md., , Jun Ho Yang, Md., Sung Hwan Kim, Md., , Seong Ho Moon, Md., , Joung Hun Byun, Md., , Chung Eun Lee, Md., Jong Woo Kim, Md., & , Dong Hun Kang, Md. (2017). Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea A retrospective study. Medicine (United States), 96(28), e7482
Umi Fatmawati, T.K. (2019). Characteristics and the Side Effects of New MDR-TB Treatment in the Dr. Soetomo Hospital during 2016. Jurnal Respirasi, 3(3), 67
WHO, W. H. O. (2016). WHO treatment guidelines for drug-resistant tuberculosis : 2016 update. Who. https://doi.org/WHO/HTM/TB/2016.04
Widiastuti, E., Subronto, Y., & Promono, D. (2017). Determinan Kejadian multi drug resistant tuberculosis di rumah sakit Dr. Sardjito Yogyakarta. Berita Kodekteran Masyarakat, 33(7), 325–330
Yang, T.W., Park, H.O., Jang, H.N., Yang, J.H., Kim, S.H., Moon, S.H., Byun, J.H., Lee, C. E., Kim, J.W., & Kang, D.H. (2017). Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. Medicine (United States). https://doi.org/10.1097/MD.0000000000007482
Yates, T.A., Tomlinson, L.A., Bhaskaran, K., Langan, S., Thomas, S., Smeeth, L., & Douglas, I. J. (2017). Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1002457
